Emgality (Galcanezumab-gnlm) for Migraine | MyMigraineTeam

Connect with others who understand.

sign up Log in
About MyMigraineTeam
Powered By

Emgality is approved by the Food and Drug Administration (FDA) to prevent migraine in adults. Emgality is also referred to by its drug name, Galcanezumab-gnlm.

Emgality is a biologic drug – a genetically engineered antibody, or protein used by the immune system to identify and neutralize substances. Emgality is also a member of a new class of drugs called calcitonin gene-related peptide receptor (CGRP-R) antagonists. Emgality is believed to work by interfering with CGRP, a substance that dilates blood vessels and contributes to pain signals and inflammation.

How do I take it?
Prescribing information states that Emgality is administered as a subcutaneous injection once a month after initial loading doses.

Emgality comes in prefilled, single-dose syringes and pens.

Side effects
The FDA-approved label for Emgality lists injection site reactions as a common side effect.

Because Emgality is a new drug, its long-term effects are not yet known.

For more details about this treatment, visit:

Emgality.com – Lilly

FDA Greenlights Galcanezumab (Emgality) for Migraine Prevention – Medscape

Continue with Facebook
Continue with Google
Lock Icon Your privacy is our priority. By continuing, you accept our Terms of use, and our Health Data and Privacy policies.
Already a Member? Log in